Narinder Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Narinder Kaur has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Harit Kumar
Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be) University, Mullana, India
6 shared publications - Rosy Bala
Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be) University, Mullana, Haryana, India
6 shared publications - Shahbaz Aman
Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India
6 shared publications - Shalini Shriwastav
Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala- Haryana, India
5 shared publications - Adesh Kumar Saini
Department of Bio-Sciences and Technology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala-133207, India
4 shared publications - Jai Dev
Department of Microbiology, M.M. Institute of Medical Science and Research, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana
4 shared publications
Latest Publications
- 1 June 2026
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 173 (11) , 115501
Optimized and Cost-Effective Portable Electrochemical DNA Sensor for Dual-Gene Detection of Neisseria Gonorrhoeae in Patients Using In-House Printed Electrodes
In this study, a screen-printed electrode modified with gold nanoparticle-stabilized graphene quantum dots and ssDNA probe (SPPE/AuNPs@GQDs/ssDNA) based biosensor compatible with smartphone technology for electrochemical detection of Neisseria gonorrhoeae (NG) via targeting two different genes ( FitA and MsrA ) was developed. The gold stabilized graphene quantum dots (AuNPs@GQDs) were synthesized and characterized using UV–vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), fluorometry, particle analyser, zeta potential and Transmission Electron Microscopy (TEM), confirming their successful synthesis and functionalization. The electrode surface characterization was assured through Scanning Electron Microscopy (SEM), Energy Dispersive X-ray (EDX) and FTIR. The electrochemical response of biosensor was investigated using cyclic voltammetry (CV), differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The FitA and MsrA gene-based DNA sensor exhibited exceptional sensitivity, reaching 16,333.9 (μA/mm 2 )/ng, 140.38(μA/mm 2 )/ng with detection limits of 0.73 fg μl −1 , 100 fg μl −1 respectively via DPV. Selectivity and specificity studies revealed the sensor’s ability to differentiate NG DNA from non-target bacterial DNA and mismatched sequences, confirming its robustness. FitA and MsrA based validation studies using cervical swab samples further confirmed diagnostic potential and enabled cross-verification of enhanced specificity and accuracy. The portable SPPE/AuNPs@GQDs/ssDNA sensor offers a cost-effective, and highly sensitive platform for NG detection, demonstrating potential for point-of-care diagnostics.
- 1 June 2026
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 173 (11) , 115501
Optimized and Cost-Effective Portable Electrochemical DNA Sensor for Dual-Gene Detection of Neisseria Gonorrhoeae in Patients Using In-House Printed Electrodes
In this study, a screen-printed electrode modified with gold nanoparticle-stabilized graphene quantum dots and ssDNA probe (SPPE/AuNPs@GQDs/ssDNA) based biosensor compatible with smartphone technology for electrochemical detection of Neisseria gonorrhoeae (NG) via targeting two different genes ( FitA and MsrA ) was developed. The gold stabilized graphene quantum dots (AuNPs@GQDs) were synthesized and characterized using UV–vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), fluorometry, particle analyser, zeta potential and Transmission Electron Microscopy (TEM), confirming their successful synthesis and functionalization. The electrode surface characterization was assured through Scanning Electron Microscopy (SEM), Energy Dispersive X-ray (EDX) and FTIR. The electrochemical response of biosensor was investigated using cyclic voltammetry (CV), differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The FitA and MsrA gene-based DNA sensor exhibited exceptional sensitivity, reaching 16,333.9 (μA/mm 2 )/ng, 140.38(μA/mm 2 )/ng with detection limits of 0.73 fg μl −1 , 100 fg μl −1 respectively via DPV. Selectivity and specificity studies revealed the sensor’s ability to differentiate NG DNA from non-target bacterial DNA and mismatched sequences, confirming its robustness. FitA and MsrA based validation studies using cervical swab samples further confirmed diagnostic potential and enabled cross-verification of enhanced specificity and accuracy. The portable SPPE/AuNPs@GQDs/ssDNA sensor offers a cost-effective, and highly sensitive platform for NG detection, demonstrating potential for point-of-care diagnostics.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3360-3369
Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens
The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical in vitro and in vivo studies demonstrate that NAC, when combined with β-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-β-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by β-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad β-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections.
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3360-3369
Open AccessNacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens
The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical in vitro and in vivo studies demonstrate that NAC, when combined with β-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-β-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by β-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad β-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections.
- Open Access
- 30 January 2026
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 20 (1) , 260
Limited Therapeutic Options in blaNDM and blaOXA-48 producing Carbapenem-resistant Klebsiella pneumoniae: Insights from a Cross-sectional Study
Carbapenem-resistant K. pneumoniae (CRKP), listed in the WHO 2024 priority, hydrolyzes β-lactam antibiotics, especially carbapenems, posing a significant challenge. Carbapenems are the last resort antibiotics for severe Gram-negative infections and are associated with increased mortality in ICUs and IPDs. This cross-sectional study at a tertiary hospital (April 2023-December 2024) included 375 multidrug-resistant (MDR) K. pneumoniae isolates with ertapenem MIC ≥8 µg/mL. Carbapenemase genes were detected via conventional PCR. Bivariate analysis examined clinical correlations, while MIC50/90 assessed resistance. The most common carbapenemase genes were blaNDM (48.26%) and blaOXA-48 (37.86%), followed by blaKPC (13.6%). Co-occurrence of genes was also reported. Twelve of seventeen clinical variables were significantly associated with gene presence (p < 0.05). Ertapenem, imipenem, and meropenem had MIC50/90 ≥8 µg/mL, indicating high resistance. Tigecycline showed better sensitivity, with MIC50/90 of 0.5/2 µg/mL (blaNDM) and 2/2 µg/mL (blaOXA-48). Fosfomycin MIC90 in blaOXA-48 isolates ranged up to 256 µg/mL. The study highlights high blaNDM and blaOXA-48 prevalence, their clinical associations, and limited therapeutic options. Tigecycline remains most effective in vitro, but pharmacokinetic concerns exist. These findings emphasize the need for antimicrobial stewardship and molecular surveillance.
- 30 January 2026
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 20 (1) , 260
Open AccessLimited Therapeutic Options in blaNDM and blaOXA-48 producing Carbapenem-resistant Klebsiella pneumoniae: Insights from a Cross-sectional Study
Carbapenem-resistant K. pneumoniae (CRKP), listed in the WHO 2024 priority, hydrolyzes β-lactam antibiotics, especially carbapenems, posing a significant challenge. Carbapenems are the last resort antibiotics for severe Gram-negative infections and are associated with increased mortality in ICUs and IPDs. This cross-sectional study at a tertiary hospital (April 2023-December 2024) included 375 multidrug-resistant (MDR) K. pneumoniae isolates with ertapenem MIC ≥8 µg/mL. Carbapenemase genes were detected via conventional PCR. Bivariate analysis examined clinical correlations, while MIC50/90 assessed resistance. The most common carbapenemase genes were blaNDM (48.26%) and blaOXA-48 (37.86%), followed by blaKPC (13.6%). Co-occurrence of genes was also reported. Twelve of seventeen clinical variables were significantly associated with gene presence (p < 0.05). Ertapenem, imipenem, and meropenem had MIC50/90 ≥8 µg/mL, indicating high resistance. Tigecycline showed better sensitivity, with MIC50/90 of 0.5/2 µg/mL (blaNDM) and 2/2 µg/mL (blaOXA-48). Fosfomycin MIC90 in blaOXA-48 isolates ranged up to 256 µg/mL. The study highlights high blaNDM and blaOXA-48 prevalence, their clinical associations, and limited therapeutic options. Tigecycline remains most effective in vitro, but pharmacokinetic concerns exist. These findings emphasize the need for antimicrobial stewardship and molecular surveillance.
- Open Access
- 14 July 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (7) , 002039
Fosfomycin resistance in extended-spectrum beta-lactamase producing Escherichia coli isolated from urinary tract-infected patients in a tertiary care hospital
Introduction. Urinary tract infections (UTIs) are a significant global health concern, with Escherichia coli being the predominant pathogen responsible for uncomplicated and complicated cases. Fosfomycin has emerged as a promising oral treatment option for multidrug-resistant UTIs, particularly those caused by extended-spectrum β-lactamase (ESBL)-producing E. coli. However, fosfomycin resistance has been paralleled by its irrational use and the emergence of enzymes that modify fosfomycin in ESBL-producing Enterobacteriaceae, especially in Asia. Hypothesis/Gap Statement. There is limited data on the prevalence of fosfomycin resistance among UTI patients in Northern Haryana, India. We hypothesize that demographic factors such as age, gender and patient type (inpatient vs. outpatient) may influence the prevalence of fosfomycin resistance and also provide insights into the effectiveness of fosfomycin in combating ESBL-producing E. coli infections in a tertiary care setting. Aim. This study aimed to investigate the prevalence of fosfomycin resistance among ESBL-producing E. coli among UTI patients in a tertiary care hospital. Methodology. Between March 2023 and February 2024, 7,348 urine samples were received from patients suspected of UTIs. The samples were subjected to screening using wet film examination and standard microbiological methods. Antibiotic susceptibility testing was done by VITEK-2 Compact (using an N-235 card), and ESBL production was confirmed using the combination disc diffusion test. Results. Out of 7,348 urine samples, 1,176 (16%) were culture-positive, with E. coli accounting for 57% of the isolates. Among the 385 E. coli isolates, 224 (58%) were ESBL producers. Fosfomycin demonstrated high efficacy, with 95% susceptibility among ESBL-producing E. coli and 96% among non-ESBL producers. However, 5% of ESBL-producing E. coli isolates were resistant to fosfomycin. Resistance to other antibiotics, such as nalidixic acid (98%) and ampicillin (93%), was notably high. No significant associations were found between ESBL production and demographic factors such as age, gender or patient type (outpatient vs. inpatient). Conclusion. Fosfomycin remains a highly effective treatment option for ESBL-producing E. coli UTIs in Northern Haryana, India, with low resistance rates observed. However, the emergence of fosfomycin resistance, albeit minimal, highlights the need for continuous surveillance and rational use of antibiotics to combat the growing threat of antimicrobial resistance.
- 14 July 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (7) , 002039
Open AccessFosfomycin resistance in extended-spectrum beta-lactamase producing Escherichia coli isolated from urinary tract-infected patients in a tertiary care hospital
Introduction. Urinary tract infections (UTIs) are a significant global health concern, with Escherichia coli being the predominant pathogen responsible for uncomplicated and complicated cases. Fosfomycin has emerged as a promising oral treatment option for multidrug-resistant UTIs, particularly those caused by extended-spectrum β-lactamase (ESBL)-producing E. coli. However, fosfomycin resistance has been paralleled by its irrational use and the emergence of enzymes that modify fosfomycin in ESBL-producing Enterobacteriaceae, especially in Asia. Hypothesis/Gap Statement. There is limited data on the prevalence of fosfomycin resistance among UTI patients in Northern Haryana, India. We hypothesize that demographic factors such as age, gender and patient type (inpatient vs. outpatient) may influence the prevalence of fosfomycin resistance and also provide insights into the effectiveness of fosfomycin in combating ESBL-producing E. coli infections in a tertiary care setting. Aim. This study aimed to investigate the prevalence of fosfomycin resistance among ESBL-producing E. coli among UTI patients in a tertiary care hospital. Methodology. Between March 2023 and February 2024, 7,348 urine samples were received from patients suspected of UTIs. The samples were subjected to screening using wet film examination and standard microbiological methods. Antibiotic susceptibility testing was done by VITEK-2 Compact (using an N-235 card), and ESBL production was confirmed using the combination disc diffusion test. Results. Out of 7,348 urine samples, 1,176 (16%) were culture-positive, with E. coli accounting for 57% of the isolates. Among the 385 E. coli isolates, 224 (58%) were ESBL producers. Fosfomycin demonstrated high efficacy, with 95% susceptibility among ESBL-producing E. coli and 96% among non-ESBL producers. However, 5% of ESBL-producing E. coli isolates were resistant to fosfomycin. Resistance to other antibiotics, such as nalidixic acid (98%) and ampicillin (93%), was notably high. No significant associations were found between ESBL production and demographic factors such as age, gender or patient type (outpatient vs. inpatient). Conclusion. Fosfomycin remains a highly effective treatment option for ESBL-producing E. coli UTIs in Northern Haryana, India, with low resistance rates observed. However, the emergence of fosfomycin resistance, albeit minimal, highlights the need for continuous surveillance and rational use of antibiotics to combat the growing threat of antimicrobial resistance.
- Open Access
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2118-2132
Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens
Antimicrobial peptides (AMPs) are varied naturally occurring compounds that are crucial to the innate immune system among several organisms. These peptides are effective against various bacteria, viruses, fungus, and cancer cells. Alternative therapeutic options are becoming more important as drug-resistant diseases become a global concern nowadays. AMPs unique modes of action and benefits over traditional antibiotics make them potential candidates for improving drug-resistant disease treatment. The capacity to target microbial membranes, alter intracellular processes, and bypass resistance systems distinguishes AMPs, making it challenging to develop resistance. This review examines how AMPs can combat drug-resistant bacteria and also, emphasizes on the broad-spectrum antibacterial properties of AMPs and their many mechanisms like, AMPs can permeabilize bacterial membranes, limit biofilm formation, and alter immune responses, making them promising therapeutics for infections that defy conventional treatments. As antibiotic resistance threatens global health, AMPs offer a possible path for next-generation antimicrobials. Export
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2118-2132
Open AccessAntimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens
Antimicrobial peptides (AMPs) are varied naturally occurring compounds that are crucial to the innate immune system among several organisms. These peptides are effective against various bacteria, viruses, fungus, and cancer cells. Alternative therapeutic options are becoming more important as drug-resistant diseases become a global concern nowadays. AMPs unique modes of action and benefits over traditional antibiotics make them potential candidates for improving drug-resistant disease treatment. The capacity to target microbial membranes, alter intracellular processes, and bypass resistance systems distinguishes AMPs, making it challenging to develop resistance. This review examines how AMPs can combat drug-resistant bacteria and also, emphasizes on the broad-spectrum antibacterial properties of AMPs and their many mechanisms like, AMPs can permeabilize bacterial membranes, limit biofilm formation, and alter immune responses, making them promising therapeutics for infections that defy conventional treatments. As antibiotic resistance threatens global health, AMPs offer a possible path for next-generation antimicrobials. Export
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 20 (1)
Comparative evaluation of various disc elution methods for the detection of colistin-resistant gram-negative bacteria
Objectives: The current study was designed to determine the performance of colistin broth disc elution (CBDE), colistin broth micro elution (CBME), and microplate elution (MPE) methods with the broth microdilution (BMD) reference method. Methods: For the study, multidrug-resistant Gram-negative bacilli (MDR GNB) isolates (n=715) obtained from various clinical specimens were tested for colistin sensitivity testing using CBDE, CBME, and MPE methods, and the results were compared with the BMD reference method. Results: Of the total MDR-GNB isolates (n=715), 6.83 % (n=49) were colistin-resistant, while none yielded the mcr gene. The CBDE method demonstrated a sensitivity (95.91 %), specificity (100 %), positive predictive value (PPV) of 100 %, and negative predictive value (NPV) of 99.7 % when compared to the reference BMD method. The CBME method yielded 93.87 %, 93.33 %, 51.11 %, and 99.7 % of sensitivity, specificity, PPV, and NPV against the reference BMD method. However, the MPE method demonstrated sensitivity (91.83 %), specificity (92.64 %), PPV (47.36 %), and NPV (99.32 %), respectively, when compared to the reference BMD method. Conclusions: The CBDE method has the potential to replace the BMD method for detecting colistin resistance among Gram-negative bacteria in laboratories. It offers a cost-effective and easy-to-learn alternative, while ensuring strong sensitivity and specificity compared to the BMD reference method.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 20 (1)
Open AccessComparative evaluation of various disc elution methods for the detection of colistin-resistant gram-negative bacteria
Objectives: The current study was designed to determine the performance of colistin broth disc elution (CBDE), colistin broth micro elution (CBME), and microplate elution (MPE) methods with the broth microdilution (BMD) reference method. Methods: For the study, multidrug-resistant Gram-negative bacilli (MDR GNB) isolates (n=715) obtained from various clinical specimens were tested for colistin sensitivity testing using CBDE, CBME, and MPE methods, and the results were compared with the BMD reference method. Results: Of the total MDR-GNB isolates (n=715), 6.83 % (n=49) were colistin-resistant, while none yielded the mcr gene. The CBDE method demonstrated a sensitivity (95.91 %), specificity (100 %), positive predictive value (PPV) of 100 %, and negative predictive value (NPV) of 99.7 % when compared to the reference BMD method. The CBME method yielded 93.87 %, 93.33 %, 51.11 %, and 99.7 % of sensitivity, specificity, PPV, and NPV against the reference BMD method. However, the MPE method demonstrated sensitivity (91.83 %), specificity (92.64 %), PPV (47.36 %), and NPV (99.32 %), respectively, when compared to the reference BMD method. Conclusions: The CBDE method has the potential to replace the BMD method for detecting colistin resistance among Gram-negative bacteria in laboratories. It offers a cost-effective and easy-to-learn alternative, while ensuring strong sensitivity and specificity compared to the BMD reference method.
- Open Access
- 1 September 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4954-4963
The pandemic’s unseen wounds: COVID-19’s profound effects on mental health
Objective: This review aims to explore the impact of the COVID-19 pandemic on mental health, with a focus on the physiological and psychological consequences, including comorbidities. The goal is to understand the direct and indirect populations affected by mental distress and identify potential interventions. Methodology: A comprehensive literature search was conducted using various databases, including Google Scholar, ResearchGate, ScienceDirect, PubMed, PLoS One, and Web of Science. The search utilized relevant keywords to investigate the direct and indirect impacts of COVID-19 on mental health. The selected articles were critically evaluated and analyzed to identify key findings and insights. Main findings: Mental health, being an intrinsic component of overall well-being, plays a vital role in physiological functioning. The COVID-19 pandemic, caused by the emergence of the novel SARS-CoV-2 virus, has had a devastating global impact. Beyond the respiratory symptoms, individuals recovering from COVID-19 commonly experience additional ailments, such as arrhythmia, depression, anxiety, and fatigue. Healthcare professionals on the frontlines face an elevated risk of mental illness. However, it is crucial to recognize that the general population also grapples with comparable levels of mental distress. Conclusion: The COVID-19 pandemic has underscored the significance of addressing mental health concerns. Various strategies can help mitigate the impact, including counselling, fostering open lines of communication, providing mental support, ensuring comprehensive patient care, and administering appropriate medications. In severe cases, treatment may involve the supplementation of essential vitamins and antidepressant therapy. By understanding the direct and indirect impacts of COVID-19 on mental health, healthcare providers and policymakers can develop targeted interventions to support individuals and communities affected by the pandemic. Continued research and collaborative efforts are essential to address this pervasive issue effectively.
- 1 September 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4954-4963
Open AccessThe pandemic’s unseen wounds: COVID-19’s profound effects on mental health
Objective: This review aims to explore the impact of the COVID-19 pandemic on mental health, with a focus on the physiological and psychological consequences, including comorbidities. The goal is to understand the direct and indirect populations affected by mental distress and identify potential interventions. Methodology: A comprehensive literature search was conducted using various databases, including Google Scholar, ResearchGate, ScienceDirect, PubMed, PLoS One, and Web of Science. The search utilized relevant keywords to investigate the direct and indirect impacts of COVID-19 on mental health. The selected articles were critically evaluated and analyzed to identify key findings and insights. Main findings: Mental health, being an intrinsic component of overall well-being, plays a vital role in physiological functioning. The COVID-19 pandemic, caused by the emergence of the novel SARS-CoV-2 virus, has had a devastating global impact. Beyond the respiratory symptoms, individuals recovering from COVID-19 commonly experience additional ailments, such as arrhythmia, depression, anxiety, and fatigue. Healthcare professionals on the frontlines face an elevated risk of mental illness. However, it is crucial to recognize that the general population also grapples with comparable levels of mental distress. Conclusion: The COVID-19 pandemic has underscored the significance of addressing mental health concerns. Various strategies can help mitigate the impact, including counselling, fostering open lines of communication, providing mental support, ensuring comprehensive patient care, and administering appropriate medications. In severe cases, treatment may involve the supplementation of essential vitamins and antidepressant therapy. By understanding the direct and indirect impacts of COVID-19 on mental health, healthcare providers and policymakers can develop targeted interventions to support individuals and communities affected by the pandemic. Continued research and collaborative efforts are essential to address this pervasive issue effectively.
- Open Access
- 22 August 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (35) , 31575-31599
Superficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges
The most prevalent infection in the world is dermatophytosis, which is a major issue with high recurrence and can affect the entire body including the skin, hair, and nails. The major goal of this Review is to acquire knowledge about cutting-edge approaches for treating dermatophytosis efficiently by adding antifungals to formulations based on nanocarriers in order to overcome the shortcomings of standard treatment methods. Updates on nanosystems and research developments on animal and clinical investigations are also presented. Along with the currently licensed formulations, the investigation also emphasizes novel therapies and existing therapeutic alternatives that can be used to control dermatophytosis. The Review also summarizes recent developments on the prevalence, management approaches, and disadvantages of standard dosage types. There are a number of therapeutic strategies for the treatment of dermatophytosis that have good clinical cure rates but also drawbacks such as antifungal drug resistance and unfavorable side effects. To improve therapeutic activity and get around the drawbacks of the traditional therapy approaches for dermatophytosis, efforts have been described in recent years to combine several antifungal drugs into new carriers. These formulations have been successful in providing improved antifungal activity, longer drug retention, improved effectiveness, higher skin penetration, and sustained drug release.
- 22 August 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (35) , 31575-31599
Open AccessSuperficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges
The most prevalent infection in the world is dermatophytosis, which is a major issue with high recurrence and can affect the entire body including the skin, hair, and nails. The major goal of this Review is to acquire knowledge about cutting-edge approaches for treating dermatophytosis efficiently by adding antifungals to formulations based on nanocarriers in order to overcome the shortcomings of standard treatment methods. Updates on nanosystems and research developments on animal and clinical investigations are also presented. Along with the currently licensed formulations, the investigation also emphasizes novel therapies and existing therapeutic alternatives that can be used to control dermatophytosis. The Review also summarizes recent developments on the prevalence, management approaches, and disadvantages of standard dosage types. There are a number of therapeutic strategies for the treatment of dermatophytosis that have good clinical cure rates but also drawbacks such as antifungal drug resistance and unfavorable side effects. To improve therapeutic activity and get around the drawbacks of the traditional therapy approaches for dermatophytosis, efforts have been described in recent years to combine several antifungal drugs into new carriers. These formulations have been successful in providing improved antifungal activity, longer drug retention, improved effectiveness, higher skin penetration, and sustained drug release.